Rhinomed Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Michael Johnson

Geschäftsführender

AU$531.6k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	69.8%
Amtszeit als Geschäftsführer	11yrs
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.5yrs

Jüngste Management Updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Michael Johnson im Vergleich zu den Einnahmen von Rhinomed verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2023	AU$532k	AU$371k	-AU$11m
Mar 31 2023	n/a	n/a	-AU$9m
Dec 31 2022	n/a	n/a	-AU$7m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$369k	AU$301k	-AU$5m
Mar 31 2022	n/a	n/a	-AU$6m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$2m	AU$304k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$7m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$1m	AU$304k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$8m
Dec 31 2019	n/a	n/a	-AU$8m
Sep 30 2019	n/a	n/a	-AU$7m
Jun 30 2019	AU$748k	AU$305k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$5m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$363k	AU$255k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$5m
Sep 30 2017	n/a	n/a	-AU$5m
Jun 30 2017	AU$672k	AU$231k	-AU$4m

Vergütung im Vergleich zum Markt: MichaelDie Gesamtvergütung ($USD347.11K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Australian ($USD297.98K).

Entschädigung vs. Einkommen: MichaelDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Michael Johnson

11yrs

Amtszeit

AU$531,600

Vergütung

Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Johnson	CEO, MD & Executive Director	11yrs	AU$531.60k	0.64% A$ 73.9k
Ross MacDonald	Member of the Medical Advisory Board	no data	keine Daten	keine Daten
Ronald Dewhurst	Independent Non-Executive Chairman	8.2yrs	AU$110.00k	6.88% A$ 792.3k
Steve Harris	Member of the Medical Advisory Board	no data	keine Daten	keine Daten
Lynette Swinburne	Non-Executive Director	1.4yrs	AU$58.45k	0.062% A$ 7.1k
John McBain	Non-Executive Director	2.8yrs	AU$73.33k	18.43% A$ 2.1m

5.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: RNODie Vorstandsmitglieder gelten als erfahren (5.5 Jahre durchschnittliche Amtszeit).

Rhinomed Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit